ASMB - Assembly Biosciences, Inc.
After hours:
Chart Events
Double Top
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.9578 |
| Open | 0.9710 |
| Bid | 1.0900 x 1300 |
| Ask | 1.1600 x 1400 |
| Day's Range | 0.9320 - 1.1500 |
| 52 Week Range | 0.7700 - 2.4200 |
| Volume | |
| Avg. Volume | 220,155 |
| Market Cap | 57.855M |
| Beta (5Y Monthly) | 0.69 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.8200 |
| Earnings Date | Aug 07, 2023 - Aug 11, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.50 |
Fair Value
Related Research
GlobeNewswireAssembly Biosciences to Present During the 2023 Jefferies Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 23, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Jason Okazaki, chief executive officer and president, and William Delaney, PhD, chief scientific officer, will present in a fireside chat during the 2023 Jefferies Healthcare Conference at 4:00 p.m. Eastern Time on June 7, 2023. A live webcast will be available on the Ev
- GlobeNewswire
Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights
Herpesvirus candidate ABI-5366 progressing towards IND and planned to enter the clinic in the first half of 2024Additional development candidate nomination anticipated in 2023Multiple abstracts accepted for presentation at EASL 2023 in June SOUTH SAN FRANCISCO, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today reported financial results and recent highlig
- GlobeNewswire
Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update
Phase 1a clinical data for remaining 200 mg multiple dose cohort for ABI-4334 continue to demonstrate encouraging clinical profile with strong projected activity against both viral replication and cccDNA formationAssembly Bio will evaluate partnering options for its core inhibitor portfolio prior to further clinical development of the mechanism for HBV cure The company will prioritize resources on its promising portfolio of antiviral programs with a faster path to clinical proof of concept, incl
Simply Wall St.Companies Like Assembly Biosciences (NASDAQ:ASMB) Could Be Quite Risky
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
- GlobeNewswire
Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights
Prioritization of core inhibitor candidate ABI-4334 and pausing of core inhibitor candidate ABI-H3733 based on data to date from ongoing clinical Phase 1 studies of both candidates and chronic toxicology observation for ABI-H3733Phase 1a complete clinical data for all ABI-4334 dose cohorts expected in April 2023Advancing expanded research portfolio, with additional development candidate nomination anticipated in 2023 and IND/CTA submission for herpesvirus candidate ABI-5366 planned for the first
- GlobeNewswire
Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes
−ABI-5366 Demonstrates Favorable Profile for a Long-Acting Therapeutic in Preclinical Studies −IND-Enabling Studies Initiating for 5366, Supporting Anticipated IND/CTA Filing in 1H2024 SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced the selection of development candidate ABI-5366 (5366) to progress to IND-e
BenzingaAssembly Biosciences Shares Gain After Promising Early Cut Data From HBV Infection Programs
Assembly Biosciences Inc (NASDAQ: ASMB) announced interim efficacy, safety, and pharmacokinetic (PK) results from a Phase 1b study of ABI-H3733 (3733) and a Phase 1a study of ABI-4334 (4334). For the Phase 1b trial of 3733, the dose selected for the first cohort was 50 mg. A dose of 100 mg has been selected for the third cohort, for which dosing is ongoing, with initial data anticipated in Q1 of 2023. Related: Disappointing Data Forces Assembly Bio Stop Combo Trial For HBV Infection. In the 50 m
- GlobeNewswire
Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334
In initial ABI-H3733 cohort of 50 mg in 28-day Phase 1b study, six of eight HBV patients on treatment reached lower limit of quantification for HBV DNA by day 21 and patients showed a mean reduction of 3.1 logs in plasma HBV DNAInitial ABI-4334 Phase 1a single-dose 30 mg cohort demonstrated pharmacokinetic profile supportive of once-daily oral dosing and provides early indication that ABI-4334's very high potency seen preclinically can be accessed clinicallyNo serious adverse events or significa
- GlobeNewswire
Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334
Healthy volunteer study will inform development of 4334 for treatment of hepatitis B virus SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that the first subject has been dosed in the Phase 1a trial of its investigational core inhibitor ABI-4334 (4334). 4334 is an investigat
ZacksAfter Plunging 17% in 4 Weeks, Here's Why the Trend Might Reverse for Assembly Biosciences (ASMB)
The heavy selling pressure might have exhausted for Assembly Biosciences (ASMB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- GlobeNewswire
Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation
Phase 1a Trial of Next-Generation Core Inhibitor, ABI-4334, Now Underway Following Clinical Trial Application (CTA) Clearance SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced financial results and recent highlights for the third quarter ended September 30, 2022. “During the t
- GlobeNewswire
Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV
Data demonstrating nanomolar potency of core inhibitor ABI-4334 to disrupt the hepatitis B virus (HBV) life cycle at multiple points supports advancement into clinical studies First data presented on preclinical characterization of potent, orally bioavailable viral entry inhibitors for HBV and hepatitis D virus (HDV) First data presented on novel series of orally bioavailable small molecule interferon-a receptor (IFNAR) agonists designed to inhibit HBV and engage the immune system with potential
- GlobeNewswire
Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®
Four poster presentations, including two late breaking, highlight breadth and promise of virology portfolio Data demonstrating preclinical activity of next-generation core inhibitor ABI-4334 against hepatitis B virus supports planned advancement into clinical studies before year end SOUTH SAN FRANCISCO, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis
- Simply Wall St.
Can Assembly Biosciences (NASDAQ:ASMB) Afford To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- GlobeNewswire
Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A. Okazaki as Successor
Dr. McHutchison will continue to provide strategic counsel as board member and chairman of the Science & Technology Committee of the boardSOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that John G. McHutchison, AO, MD, chief executive officer (CEO), will retire as CEO at th
- GlobeNewswire
Assembly Biosciences to Host Webcast on August 31, 2022, Introducing Two New Research Programs Targeting Recurrent HSV-2 Infection and Transplant-Associated Herpesvirus Diseases
- Renowned virologist, Nobel laureate and Assembly Bio board member, Sir Michael Houghton, PhD, will join company leadership for the discussion - SOUTH SAN FRANCISCO, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus and other viral diseases, plans to host a research webcast on Wednesday, August 31, 2022, from 1:30-2:30 pm PT/4:30-5:30 pm ET. T
- GlobeNewswire
Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced financial results and recent highlights for the second quarter ended June 30, 2022. “We are excited to advance clinical development of our next-generation, more potent core inhibitors and to continue the expansion of our pipeli
ZacksAssembly Biosciences (ASMB) Upgraded to Strong Buy: Here's Why
Assembly Biosciences (ASMB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ZacksBest Momentum Stocks to Buy for August 4th
PI, INST and ASMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 4, 2022.
ZacksNew Strong Buy Stocks for August 4th
ARI, CB, PI, ASMB and URI have been added to the Zacks Rank #1 (Strong Buy) List on August 4, 2022.
- Simply Wall St.
The past five years for Assembly Biosciences (NASDAQ:ASMB) investors has not been profitable
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...
BenzingaDisappointing Data Forces Assembly Bio Stop Combo Trial For HBV Infection
Assembly Biosciences Inc (NASDAQ: ASMB) will stop working on its first-generation core inhibitor, vebicorvir (VBR), as it prioritizes its next-gen core inhibitors ABI-H3733 and ABI-4334 and advances its research pipeline. The decision follows the review of interim efficacy from the two triple combination studies that did not show a benefit in multiple key viral parameters compared to the combinations without VBR. Phase 1b trial of ABI-H3733 in chronic HBV infection is underway. Initial data are
- GlobeNewswire
Assembly Biosciences Announces Program Reprioritization and Organizational Update
- Discontinues clinical development of vebicorvir, Assembly Bio’s first-generation core inhibitor, based on interim efficacy data from ongoing combination clinical studies - Advancing next-generation, significantly more potent core inhibitors, ABI-H3733 and ABI-4334, in clinical studies - Prioritizes research activities including small molecule HBV/HDV entry inhibitor, small molecule interferon-α receptor agonist and two additional undisclosed viral targets - Reprioritized clinical programs and
- GlobeNewswire
Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL’s International Liver Congress™ 2022
SOUTH SAN FRANCISCO, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced data from the company’s investigational core inhibitor programs ABI-H3733 (3733), ABI-4334 (4334) and vebicorvir (VBR), featured in six poster presentations at the International Liver Congress™, the Annual Meeting of the Europe
InvestorPlace7 Penny Stocks That Could Triple in 2022
The definition varies with countries but in the U.S., a penny stock is one which is trading under $5 and is often referred to as a micro-cap. A micro-cap is a company whose market capitalization is between $50 million and $300 million. These stocks trade mostly over the counter, rather than on main U.S. exchanges. But there are exceptions. You can find a few trading on the main exchanges as well, either U.S. or overseas or both. A chief pushback against penny stock investing is the illiquid natu